Nasdaq vktx.

Viking Therapeutics last announced its quarterly earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per share).Find the latest analyst research for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.For Viking Therapeutics (NASDAQ: VKTX) that’s exactly what investors get. VKTX has currently five drugs in its development pipeline. Those drugs are targeting a variety of diseases including ...Viking Therapeutics, Inc. (NASDAQ:VKTX) is a biotechnology company that has joined the obesity drug race and is manufacturing experimental weight loss drugs such as the VK2735. It is based in San ...SAN DIEGO, Aug. 2, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

Strong Quarter-End Cash Position of $393M. SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the ...

Nasdaq Futures. 15,979.75 ... (NASDAQ:VKTX), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the …

Apr 3, 2023 · SAN DIEGO, April 3, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ... View Viking Therapeutics, Inc VKTX investment & stock information. Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Discover historical prices for VKTX stock on Yahoo Finance. View daily, weekly or monthly format back to when Viking Therapeutics, Inc. stock was issued.Viking Therapeutics (VKTX 4.42%), a small-cap biotech, has been on quite the ride over the past few months.Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival ...

Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added ~39% pre-market Tuesday after announcing that its obesity candidate VK2735 led to an average body weight reduction of up to ~8% in a ...

Shares of clinical-stage biotech Viking Therapeutics ( VKTX 6.68%) fell by as much as 4.8% on exceptionally low volume during the first hour of trading Tuesday morning. Since this mid-single-digit ...

Nasdaq Futures. 15,979.75 ... (NASDAQ:VKTX), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 74% ownership.(NASDAQ: VKTX) Viking Therapeutics's market cap is $978.28M, as of Nov 12, 2023. Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares. Viking Therapeutics 's market cap is calculated by multiplying VKTX 's current stock price of $9.78 by VKTX 's total outstanding shares of 100,028,953 .Apr 4, 2023 · Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ... Viking Therapeutics Inc (NASDAQ:VKTX) Viking Therapeutics Inc. 13.01. Delayed Data. As of Dec 01. +0.79 / +6.42%. Today’s Change. 3.54. Today ||| 52-Week Range.VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock ...

VKTXNASDAQ 12.28USD +0.72 +6.23% At close at Nov 24, 13:58 UTC-8 See on Supercharts Overview News Ideas Financials Technicals Forecast VKTX chart Today 6.23% 5 days 16.40% 1 month 15.20% 6 months …SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the company's 12-week Phase 2 study of VK2809 in patients with non …View Premium Services. Real time Viking Therapeutics (VKTX) stock price quote, stock graph, news & analysis.29 mar 2023 ... ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...Viking Therapeutics Inc (NASDAQ:VKTX) Viking Therapeutics Inc. 13.01. Delayed Data. As of Dec 01. +0.79 / +6.42%. Today’s Change. 3.54. Today ||| 52-Week Range.VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock ...VDOMDHTMLhtml>. Viking Therapeutics, Inc. Common Stock (VKTX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.

Looking at the chart above, VKTX's low point in its 52 week range is $2.5345 per share, with $25.7199 as the 52 week high point — that compares with a last trade of $15.54.Viking Therapeutics (NASDAQ: VKTX) is one of the more exciting biopharma stocks out there. The firm is developing novel therapies to address endocrine and metabolic disorders. It has more than ...

VKTXNASDAQ 12.28USD +0.72 +6.23% At close at Nov 24, 13:58 UTC-8 See on Supercharts Overview News Ideas Financials Technicals Forecast VKTX chart Today 6.23% 5 days 16.40% 1 month 15.20% 6 months …Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.SAN DIEGO, Jan. 3, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Clinical-stage biotech Viking Therapeutics ( VKTX 6.23%) is having another tough trading session. As of 1:40 p.m. ET Tuesday, Viking's stock was down by 19.8% on higher-than-normal volume ...Stock Ratings Screener · Free Ratings Newsletter. This page (NASDAQ:VKTX) was last updated on 12/4/2023 by ...VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock ...

SAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

Find real-time VKTX - Viking Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.

Fintel reports that on May 8, 2023, HC Wainwright & Co. reiterated coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation. Analyst Price Forecast Suggests 20.92% Upside. As of ...Maybe you’ve never invested before. Maybe you have no clue what the difference is between NASDAQ and the New York Stock Exchange. Regardless, the name Charles Schwab probably rings a bell.VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 55% based on the firm’s underlying fundamentals and the stock ...02 Feb, 2018, 08:33 ET. SAN DIEGO, Feb. 2, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel ...He does not neglect the obesity-centered candidate VK2735, however, and writes, “We view VKTX’s lead candidate THR-β agonist VK2809 for NASH as similar to Madrigal Pharmaceutical’s MGL-3196 ...Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 13.01 +0.79 (+6.46%) At close: 04:00PM EST. 13.10 +0.09 (+0.69%) After hours: 07:47PM EST. Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Oct 25, 2023Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added 15% on Monday after Roche (OTCQX:RHHBY) agreed to acquire a peer obesity drugmaker Carmot Therapeutics (CRMO) in a up to $3.1B deal ... Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced... Oct 25, 2023

Simply Wall St ™. Simply Wall Street Pty Ltd. Level 7, 320 Pitt Street, Sydney. Popular Markets. US AU UK IN CA ZA. About Us Careers. Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927).Viking Therapeutics Inc (Symbol: VKTX) saw options trading volume of 5,067 contracts, representing approximately 506,700 underlying shares or approximately 53.5% of VKTX's average daily trading ...Strong Quarter-End Cash Position of $376M. SAN DIEGO, Oct. 25, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the ...Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Instagram:https://instagram. vanguard wellington fundsbankrupt businessesstock broker germanymermaran SAN DIEGO, April 3, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Turning to the calls side of the option chain, the call contract at the $18.00 strike price has a current bid of $1.05. If an investor was to purchase shares of VKTX stock at the current price ... franklin rising dividend fundfistrade Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 13.01 +0.79 (+6.46%) At close: 04:00PM EST. 13.10 +0.09 (+0.69%) After hours: 07:47PM EST. fbkwx 29 mar 2023 ... ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine ...Dec 1, 2023 · According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00. Dec 4, 2023 · Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders. Insiders own 5.89% of the company shares, while shares held by institutions stand at 68.75% with a share float percentage of 73.05%. Investors are also buoyed by the number of investors in a company, with Viking Therapeutics Inc having a total of 246 institutions that hold shares in the ...